Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 306-313

  Joerger, M ^a   Baty, F ^a   Fruh M ^a   Droege, C ^b   Stahel, R A ^c   Betticher, D C ^d   von Moos, R ^e   Ochsenbein, A ^f   Pless, M ^g   Gautschi, O ^h   Rothschild, S ^h   Brauchli, P ⁱ   Klingbiel, D ⁱ   Zappa, F ^j   Brutsche, M ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Hopital Cantonal de Fribourg   (Switzerland)

^e KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^f PSI   (Switzerland)

^g CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^h LUZERNER KANTONSSPITAL   (Switzerland)

ⁱ SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^j Reparto di Chirurgia Ortopedica   (Switzerland)

more..

Author keywords

Bevacizumab; Biomarkers; Chemotherapy; Erlotinib; Lung cancer; MicroRNA's

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; GEMCITABINE; MICRORNA; MICRORNA 141; MICRORNA 17; MICRORNA 181C; MICRORNA 191; MICRORNA 192; MICRORNA 199A 3P; MICRORNA 215; MICRORNA 219 5P; MICRORNA 221; MICRORNA 223; MICRORNA 29A; MICRORNA 30B; MICRORNA 30C; MICRORNA 3196; MICRORNA 362 3P; MICRORNA 363; MICRORNA 376A; MICRORNA 424; MICRORNA 425; MICRORNA 500A; MICRORNA 502 3P; MICRORNA 542 5P; MICRORNA 557; MICRORNA 664; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NON SQUAMOUS LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REPRODUCIBILITY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PLATINUM; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 84904131148     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.04.014     Document Type: Article

References (36)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
3. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899-909.
4. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
5. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
6. Naumov G.N., Nilsson M.B., Cascone T., Briggs A., Straume O., Akslen L.A., et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009, 15:3484-3494.
7. Cohen E.E., Subramanian J., Gao F., Szeto L., Kozloff M., Faoro L., et al. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer 2012, 13:123-128.
8. Dingemans A.M., de Langen A.J., van den Boogaart V., Marcus J.T., Backes W.H., Scholtens H.T., et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Ann Oncol 2011, 22:559-566.
9. Zappa F., Droege C., Betticher D., von Moos R., Bubendorf L., Ochsenbein A., et al. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer 2012, 78(3):239-244.
10. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12.
11. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009, 106:4402-4407.
12. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
13. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
14. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
15. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009, 10:704-714.
16. Bishop J.A., Benjamin H., Cholakh H., Chajut A., Clark D.P., Westra W.H. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010, 16:610-619.
17. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
18. Yu S.L., Chen H.Y., Chang G.C., Chen C.Y., Chen H.W., Singh S., et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008, 13:48-57.
19. Raponi M., Dossey L., Jatkoe T., Wu X., Chen G., Fan H., et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 2009, 69:5776-5783.
20. Seike M., Goto A., Okano T., Bowman E.D., Schetter A.J., Horikawa I., et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A 2009, 106:12085-12090.
21. Patnaik S.K., Kannisto E., Knudsen S., Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010, 70:36-45.
22. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
23. Griffiths-Jones S., Moxon S., Marshall M., Khanna A., Eddy S.R., Bateman A. Rfam: annotating non-coding RNAs in complete genomes. Nucleic Acids Res 2005, 33:D121-D124.
24. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36:D154-D158.
25. Bolstad B.M., Irizarry R.A., Astrand M., Speed T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
26. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
27. Yuxia M., Zhennan T., Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012, 138(12):2045-2050.
28. Zhu W., Liu X., He J., Chen D., Hunag Y., Zhang Y.K. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case-control study. BMC Cancer 2011, 11:393.
29. Plaisier C.L., Pan M., Baliga N.S. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 2012, 22:2302-2314.
30. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012, 109:E2110-E2116.
31. Gebeshuber C.A., Zatloukal K., Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009, 10:400-405.
32. Landi M.T., Zhao Y., Rotunno M., Koshiol J., Liu H., Bergen A.W., et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010, 16:430-441.
33. Rothschild S.I., Tschan M.P., Federzoni E.A., Jaggi R., Fey M.F., Gugger M., et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 2012, 31:4221-4232.
34. Kalinowski F.C., Giles K.M., Candy P.A., Ali A., Ganda C., Epis M.R., et al. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One 2012, 7:e47067.
35. Wang Y.S., Wang Y.H., Xia H.P., Zhou S.W., Schmid-Bindert G., Zhou C.C. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac J Cancer Prev 2012, 13:255-260.
36. Dacic S., Kelly L., Shuai Y., Nikiforova M.N. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status. Mod Pathol 2010, 23:1577-1582.